Trends in GLP‐1 Receptor Agonist Prescribing Without an Apparent FDA‐Approved Indication
Babak J. Orandi,
Leila Yan,
Macey L. Levan,
Holly F. Lofton,
Karan R. Chhabra,
Christine J. Ren‐Fielding,
S. Ali Husain,
Mara A. McAdams‐DeMarco,
Dorry L. Segev,
Michal A. Mankowski,
Allan B. Massie
Wiley ·
2026-10-28
· DOI 10.1002/oby.70301
Аннотация у издателя не опубликована — полный текст доступен по ссылке ниже.
Babak J. Orandi, Leila Yan, Macey L. Levan, Holly F. Lofton, Karan R. Chhabra, Christine J. Ren‐Fielding et al. Trends in GLP‐1 Receptor Agonist Prescribing Without an Apparent FDA‐Approved Indication. // Obesity. – 2026. – DOI: 10.1002/oby.70301. – URL: https://onlinelibrary.wiley.com/doi/10.1002/oby.70301?af=R
Babak J. Orandi, Leila Yan, Macey L. Levan, Holly F. Lofton, Karan R. Chhabra, Christine J. Ren‐Fielding, S. Ali Husain, Mara A. McAdams‐DeMarco, Dorry L. Segev, Michal A. Mankowski, & Allan B. Massie (2026). Trends in GLP‐1 Receptor Agonist Prescribing Without an Apparent FDA‐Approved Indication. Obesity. https://doi.org/10.1002/oby.70301
Babak J. Orandi, et al. “Trends in GLP‐1 Receptor Agonist Prescribing Without an Apparent FDA‐Approved Indication.” Obesity, 2026. doi:10.1002/oby.70301.
@article{Orandi2026,
title = {Trends in GLP‐1 Receptor Agonist Prescribing Without an Apparent FDA‐Approved Indication},
author = {Orandi, Babak J. and Yan, Leila and Levan, Macey L. and Lofton, Holly F. and Chhabra, Karan R. and Ren‐Fielding, Christine J. and Husain, S. Ali and McAdams‐DeMarco, Mara A. and Segev, Dorry L. and Mankowski, Michal A. and Massie, Allan B.},
journal = {Obesity},
year = {2026},
doi = {10.1002/oby.70301},
url = {https://onlinelibrary.wiley.com/doi/10.1002/oby.70301?af=R}
}